Journal
ONCOGENE
Volume 39, Issue 41, Pages 6406-6420Publisher
SPRINGERNATURE
DOI: 10.1038/s41388-020-01438-1
Keywords
-
Funding
- Terry Fox Research Institute Program Project Team Grant on Oncometabolism
- Canadian Institutes of Health Research (CIHR)
- CIHR [MOP-106603]
- Vanier Canada Graduate Scholarship-CIHR
- CIHR
Ask authors/readers for more resources
DNA methylation is implicated in the acquisition of malignant phenotypes, and the use of epigenetic modulating drugs is a promising anti-cancer therapeutic strategy. 5-aza-2'deoxycytidine (decitabine, 5-azadC) is an FDA-approved DNA methyltransferase (DNMT) inhibitor with proven effectiveness against hematological malignancies and more recently triple-negative breast cancer (BC). Herein, genetic or pharmacological studies uncovered a hitherto unknown feedforward molecular link between DNMT1 and the estrogen related receptor alpha (ERR alpha), a key transcriptional regulator of cellular metabolism. Mechanistically, DNMT1 promotes ERR alpha stability which in turn couples DNMT1 transcription with that of the methionine cycle and S-adenosylmethionine synthesis to drive DNA methylation. In vitro and in vivo investigation using a pre-clinical mouse model of BC demonstrated a clear therapeutic advantage for combined administration of the ERR alpha inhibitor C29 with 5-azadC. A large-scale bisulfite genomic sequencing analysis revealed specific methylation perturbations fostering the discovery that reversal of promoter hypermethylation and consequently derepression of the tumor suppressor gene,IRF4, is a factor underlying the observed BC suppressive effects. This work thus uncovers a critical role of ERR alpha in the crosstalk between transcriptional control of metabolism and epigenetics and illustrates the potential for targeting ERR alpha in combination with DNMT inhibitors for BC treatment and other epigenetics-driven malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available